10 completed. 6 Phase 2, 2 Phase 1.
By phase and status
Follow Osivax: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg OVX836 480µg, Saline Solution - Influenza | Phase 2 | Completed | 2891 | 2025-09-08 | 2026-10-16 |
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness Nasopharyngeal swabs - Influenza | | Completed | 119 | 2024-12-13 | 2025-06-25 |
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836 OVX836 shot - Vaccine-Preventable Diseases, Influenza | Phase 2 | Completed | 117 | 2024-10-22 | 2025-06-06 |
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers OVX033, Saline solution - Coronavirus | Phase 1 | Completed | 48 | 2024-01-08 | 2026-09-10 |
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. OVX836 480µg, Fluarix Tetra, Afluria Quad - Influenza | Phase 2 | Completed | 478 | 2023-05-10 | 2024-01-25 |
Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. OVX836 480µg, Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra), Placebo - Influenza | Phase 2 | Completed | 180 | 2022-05-09 | 2024-10-31 |
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness. Blood samples - Influenza | | Completed | 66 | 2021-12-01 | 2022-07-19 |
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers. OVX836-003, Saline solution - Influenza | Phase 2 | Completed | 239 | 2021-11-15 | 2023-08-31 |
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years OVX836, Quadrivalent seasonal influenza vaccine (Influvac TetraTM) - Influenza | Phase 2 | Completed | 300 | 2019-12-11 | 2022-09-22 |
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects OVX836 (Intramuscular), Placebo (Intramuscular), OVX836 (Intranasal) - Influenza | Phase 1 | Completed | 72 | 2018-06-12 | 2022-09-22 |
Conditions studied
Influenza, Human (9) · Coronavirus Infections (1) · Vaccine-Preventable Diseases (1)
Interventions
Saline Solution (3) · Blood Specimen Collection (1) · Influenza Vaccines (1) · Injections, Intramuscular (1)
Countries
Belgium (7) · Australia (2) · France (2) · Finland (1) · Germany (1)
Top investigators
Isabel Leroux-Roels, MD, PhD (3) · Nicola Groth, MD (1) · Odile Launay, MD (1) · Pierre Van Damme, MD, PhD (1) · Ross Aldrich, MBBS (1)
Results publications
PMID 35464450, PMID 37517422, PMID 40573889